

## Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer

BEDFORD, Mass., March 19, 2019 – [Stoke Therapeutics, Inc.](#) today announced the appointment of Stephen J. Tulipano, CPA, MBA as chief financial officer. Mr. Tulipano has more than 30 years of experience leading the financial operations of private and public companies in the biotechnology and healthcare industry. In this new role, Mr. Tulipano will add his deep finance experience to a management team with a proven track record in developing novel therapies for patients with rare genetic disorders.

“Steve’s expertise in operating and funding biotechnology companies will be critical as the Stoke team advances our mission to develop precision medicines for genetic epilepsies and other diseases,” said Edward M. Kaye, M.D., chief executive officer of Stoke Therapeutics. “We are thrilled to have him on our senior leadership team as we continue to advance our pipeline towards the clinic.”

Prior to joining Stoke, Mr. Tulipano served as chief financial officer and treasurer of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), where he worked with the Aldeyra team to advance multiple product candidates in orphan and non-orphan diseases, led the company’s strategic financings and completed a development and commercialization agreement with a major biopharmaceutical company, among other accomplishments. He also spent five years as chief financial officer of Javelin Pharmaceuticals, Inc., a pharmaceutical development company focused on pain relief that was acquired by Hospira, Inc. in 2010. Prior to that, Mr. Tulipano was director of corporate accounting at Biogen Inc. (NASDAQ:BIIB), where he led an accounting team supporting external reporting, research and development and manufacturing. He holds a B.S. in business administration and accounting from Salem State College and an MBA from the Sawyer School of Management at Suffolk University and is a certified public accountant.

“Stoke’s approach of upregulating protein expression to treat the underlying cause of disorders like Dravet syndrome is novel and very exciting,” Tulipano said. “I look forward to joining this team of talented scientists and leaders dedicated to developing disease-modifying therapies for patients with severe genetic diseases.”

### About Stoke Therapeutics

Launched in 2018, Stoke Therapeutics is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. Stoke is targeting a wide array of genetic conditions affecting the central nervous system, eye, liver and kidney. Its lead program is the potential first disease-modifying therapy for Dravet syndrome, a severe and progressive genetic epilepsy. To date, Stoke has raised \$130 million in funding from two rounds of financing; investors include Apple Tree Partners, RTW Investments, RA Capital Management, Cormorant Asset Management, Perceptive Advisors, funds managed by Janus Henderson Investors, Redmile Group, Sphera Funds Management and Alexandria Venture Investments. For more information, visit [www.StokeTherapeutics.com](http://www.StokeTherapeutics.com) and follow Stoke on Twitter [@StokeTx](#).

### Media Contact

Sara Green

Ten Bridge Communications  
[sgreen@tenbridgecommunications.com](mailto:sgreen@tenbridgecommunications.com)  
(617) 233-1714